Idorsia competitors and similar companiesClear all

Idorsia's competitors and similar companies include Roivant Sciences, Vifor Pharma, Ipsen, Regeneron Pharmaceuticals, Biocon, Pfizer, Roche and Novartis.
Idorsia
Idorsia
Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.
Roivant Sciences
Roivant Sciences
Roivant Sciences is a company that develops and commercializes medicines.
Vifor Pharma
Vifor Pharma
Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products.
Ipsen
Ipsen
Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases.
Biocon
Biocon
Biocon is a global biopharmaceutical company.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
Roche
Roche
Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Founding Date
Founding Date
2017
Founding Date
2014
Founding Date
1927
Founding Date
1929
Founding Date
1988
Founding Date
1978
Founding Date
1849
Founding Date
1896
Founding Date
1996
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Allschwil, CH HQ
Shanghai, CN
Lörrach, DE
Chiyoda City, JP
Locations
London, GB HQ
Basel, CH
Boston, US
New York, US
Locations
Glattbrugg, CH HQ
Buenos Aires, AR
Melbourne, AU
Melbourne, AU
Wien, AT
Antwerpen, BE
São Paulo, BR
see more
Locations
Boulogne-Billancourt, FR HQ
Glen Waverley, AU
Merelbeke, BE
Hoofddorp, NL
Locations
Tarrytown, US HQ
Halifax, CA
Mississauga, CA
München, DE
Dublin, IE
Limerick, IE
Amsterdam, NL
see more
Locations
Bengaluru, IN HQ
Bengaluru, IN
Hyderabad, IN
Visakhapatnam, IN
Dublin, IE
Kuala Lumpur, MY
Puchong, MY
see more
Locations
New York, US HQ
Buenos Aires, AR
Villa Adelina, AR
Bentley, AU
Footscray, AU
Mulgrave, AU
Sydney, AU
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
North Ryde, AU
Sydney, AU
Wien, AT
Dhaka, BD
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Employees
Employees
8007% increase
Employees
650
Employees
2,200
Employees
4,500
Employees
10,36814% increase
Employees
15,000
Employees
79,0001% increase
Employees
100,9201% decrease
Employees
104,3231% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
3.7 b
Valuation ($)
N/A
Valuation ($)
9.3 b
Valuation ($)
80.8 b
Valuation ($)
N/A
Valuation ($)
281.4 b
Valuation ($)
N/A
Valuation ($)
N/A
Twitter followers
Twitter followers
2 k
Twitter followers
1.6 k
Twitter followers
N/A
Twitter followers
5.8 k
Twitter followers
32 k
Twitter followers
21.1 k
Twitter followers
32 k
Twitter followers
246.6 k
Twitter followers
302.4 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
17
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
5
Number of tweets (last 30 days)
14
Number of tweets (last 30 days)
104
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
44
Number of tweets (last 30 days)
15
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
3.1
Average likes per tweet (last 30 days)
1.4
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
18.8
Average likes per tweet (last 30 days)
12
Average likes per tweet (last 30 days)
2.8
Average likes per tweet (last 30 days)
17.5
Average likes per tweet (last 30 days)
7.6
Average likes per tweet (last 30 days)
5.7
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
57.69%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
90.91%
Percentage of tweets with engagement (last 30 days)
66.67%
Alexa Website Rank
Alexa Website Rank
622932
Alexa Website Rank
420005
Alexa Website Rank
594160
Alexa Website Rank
425174
Alexa Website Rank
371242
Alexa Website Rank
236714
Alexa Website Rank
33980
Alexa Website Rank
46160
Alexa Website Rank
125724
Employee Rating
Employee Rating
3.7
Employee Rating
3.6
Employee Rating
3
Employee Rating
4
Employee Rating
4
Employee Rating
3.8
Employee Rating
4.2
Employee Rating
4.2
Employee Rating
4.2

Financial

Revenue (est.)
Revenue (est.)
CHF35.3m (FY, 2021)
Revenue (est.)
$55.3m (FY, 2022)
Revenue (est.)
CHF1.8b (FY, 2021)
Revenue (est.)
€2.9b (FY, 2021)
Revenue (est.)
$16.1b (FY, 2021)
Revenue (est.)
₹80.2b (FY, 2022)
Revenue (est.)
$81.3b (FY, 2021)
Revenue (est.)
CHF62.8b (FY, 2021)
Revenue (est.)
$52.9b (FY, 2021)
Cost of goods
Cost of goods
N/A
Cost of goods
$9m (FY, 2022)
Cost of goods
CHF498.7m (FY, 2021)
Cost of goods
€292.9m (FY, 2021)
Cost of goods
$2.4b (FY, 2021)
Cost of goods
₹28.8b (FY, 2022)
Cost of goods
$30.8b (FY, 2021)
Cost of goods
(CHF15.5b) (FY, 2021)
Cost of goods
$9.7b (FY, 2021)
Gross profit
Gross profit
CHF35.3m (FY, 2021)
Gross profit
$46.3m (FY, 2022)
Gross profit
CHF1.3b (FY, 2021)
Gross profit
€2.8b (FY, 2021)
Gross profit
$13.6b (FY, 2021)
Gross profit
₹58.1b (FY, 2022)
Gross profit
$50.5b (FY, 2021)
Gross profit
CHF50.4b (FY, 2021)
Gross profit
$45.1b (FY, 2021)
Net income
Net income
(CHF634.6m) (FY, 2021)
Net income
($924.1m) (FY, 2022)
Net income
CHF265.4m (FY, 2021)
Net income
€646.3m (FY, 2021)
Net income
$8.1b (FY, 2021)
Net income
₹7.7b (FY, 2022)
Net income
$22b (FY, 2021)
Net income
CHF14.9b (FY, 2021)
Net income
$24b (FY, 2021)

Operating

Manufacturing Sites
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
39 (FY, 2021)
Manufacturing Sites
23 (FY, 2019)
Manufacturing Sites
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
4 (Q2, 2021)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
27 (FY, 2021)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
5 (Q2, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
25 (FY, 2021)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
1 (Q2, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
27 (FY, 2021)
Phase III Trials Products
N/A
Phase III Trials Products
54 (FY, 2021)
Phase III Trials Products (Oncology)
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
N/A
Phase III Trials Products (Oncology)
27 (Jan, 2022)
Phase III Trials Products (Oncology)
27 (FY, 2021)
Registration Phase Products
Registration Phase Products
N/A
Registration Phase Products
1 (Q2, 2021)
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
N/A
Registration Phase Products
10 (FY, 2021)
Registration Phase Products
N/A
Registration Phase Products
8 (FY, 2021)
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
4 (FY, 2020)
US FDA Breakthrough Therapy Designations
6 (FY, 2017)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 1.9b
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 53.9m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 7.8b
Total funding raised
$ 6.5m
For sources of this data, please see the company profile

View company profiles

Roivant Sciences
HQ
London, GB
Employees
650

Roivant Sciences is a company that develops and commercializes medicines.

View company
Vifor Pharma
HQ
Glattbrugg, CH
Employees
2,200

Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products.

View company
Ipsen
HQ
Boulogne-Billancourt, FR
Employees
4,500

Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs.

View company
Regeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
10,368↑ 14% increase

Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines for the treatment of eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases.

View company